Navigation Links
Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Date:7/11/2011

itive or high-risk node-negative breast cancer.  While positive preliminary results suggested that statistically definitive results may be obtained in 2012, it was decided to enroll an additional 100 patients early in 2011 to ensure sufficient patient numbers.  In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for Herceptin.  Although 75% of breast cancer patients have some level of HER-2 expression and are eligible for AE37, only 25% have HER-2 levels high enough to be eligible for Herceptin.  The population of patients with low-to-intermediate levels of HER-2 expression currently has no treatment option.  For this reason, it is anticipated that a Phase III trial will be conducted in this specific patient population having low-to-intermediate HER-2 expression levels.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows f
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
2. Generex Provides Clarification of Facts
3. Generex Announces Results of Annual Stockholders Meeting
4. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
5. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
6. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
7. Generex Announces $3.0 Million Capital Investment
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
10. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
11. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
(Date:7/10/2014)... RICHLAND, Wash. The lithium-ion batteries that power our ... run longer on a single charge with the help ... the porous material to replace the graphite traditionally used ... more than 10 times the energy storage capacity of ... lithium-ion battery electrode was published today in Nature ...
(Date:1/15/2014)... a club sandwich at the nanoscale, National Institute ... in crafting a uniform, multi-walled carbon-nanotube-based coating that ... in upholstered furniture and other soft furnishings. , ... reduced 35 percent compared with untreated foam. As ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... David P. Wright, Co-Chair of the Alliance for ... testified today before the House Labor, Health and ... critical importance of developing drugs, vaccines and other ... and other catastrophic health emergencies. Effective medical countermeasures ...
... to Enable BBK Worldwide to Better Serve Asia-Pacific ... BBK Worldwide, a global leader in patient recruitment ... BBK Worldwide -- Osaka, G.K., in Osaka, Japan. ... pharmaceutical, biotechnology, and medical device companies, as well ...
... 18 Sopherion Therapeutics, LLC, a biopharmaceutical company ... therapies, announced that it completed enrollment in its ... (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This ... lead product in combination with the current standard ...
Cached Biology Technology:Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 3Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 2Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 3
(Date:7/11/2014)... This news release is available in German . ... imaging is a method that uses the refraction of ... absorption. The images produced with this method are often ... The scientists in the team of Prof. Franz Pfeiffer ... X-ray imaging and therapy including X-ray phase-contrast imaging. ...
(Date:7/11/2014)... develop relationships with other group members to reduce aggression ... baboons the strategy for grooming activities shows a certain ... in the scientific journal Biology Letters . , ... not practiced without ulterior motives. To be groomed has ... while grooming another individual can provide access to infants, ...
(Date:7/11/2014)... transplantation of mesenchymal stem cells can stimulate neurogenesis in ... Alzheimer,s disease (AD) and improve tissue and function injury ... reported on the therapeutic effect of adipose-derived stem cells ... effect on oxidative injury and neurogenesis in the brain ... School of Life Sciences, Tsinghua University, China transplanted ADSCs ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... predicted that tree species will respond to global warming ... a new study of 65 different species in 31 ... Nearly 80 percent of the species aren,t yet ... staying in place -- but speeding up their life ...
... Nio Southern Oscillation (ENSO), altering the cycles of El Nio ... to Australia and many other Pacific-rim countries., New research published ... has revealed how the ENSO cycle has changed over the ... an impact on the strength and timing of El Nio ...
... of multiple sclerosis, a debilitating disease that affects up to ... researchers and medical professionals for generations. But Steven Schutzer, a ... now found an important clue why progress has been slow ... MS has focused on the wrong part of the brain. ...
Cached Biology News:Climate change may speed up forests' life cycles 2Global warming could change strength of El Niño 2Multiple sclerosis appears to originate in different part of brain than long believed 2Multiple sclerosis appears to originate in different part of brain than long believed 3
Adult Bovine Serum US Origin...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 13(S)-HODE is produced by incubation of linoleic ... been shown to inhibit the adhesion of tumor ...
...
...
Biology Products: